Moreover, patients with loss of function mutations in NaV1.7 present with congenital insensitivity to pain and aside from anosmia (loss of smell) have no serious physiological deficits, highlighting the potential of NaV1.7 as a drug target for pain therapeutics [7]. The gene discussed is SCN9A; the disease is Anosmia.